The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | 10 years of researching NK-cells for MM treatment
Multiple myeloma (MM) is known to have a dysregulatory effect on the immune system; however, preclinical trials have shown that NK-cells are able to kill MM cells. In this video, Nina Shah, MD, from the University of California, San Francisco, CA, describes her 10-year-long project investigating how NK-cell immunotherapy can be used to treat patients with MM. This research has resulted in Phase I and II trials (NCT01729091) of a umbilical cord blood (CB)‐derived NK-cell therapy for MM patients undergoing high dose chemotherapy and auto‐HSCT, with promising results thus far. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL.
